J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Trump Says Anthropic No Longer Seen as National Security Threat 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
BOSTON, Dec. 11, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that it will host a conference call and webcast slide presentation on Wednesday, December 16, 2015 at 4:30 PM ET to provide a corporate update and discuss the Company's 2016 outlook.
The call can be accessed by dialing (877) 751-7350 (U.S. and Canada) or (918) 559-5237 (international). The passcode for the conference call is 6055343. To access the slide and live audio webcast, or the subsequent archived recording, visit the "Investors & Media" section of the ZIOPHARM website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company's website for two (2) weeks.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer. The Company's synthetic immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and more precisely modulate gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
CONTACT: Lori Ann Occhiogrosso
ZIOPHARM Oncology, Inc.
617-259-1987
[email protected]
David Pitts
Argot Partners
212-600-1902
[email protected]
